高级检索
宋洁梅, 温小安, 孙宏斌. 肺动脉高压发生机制及治疗药物的研究进展[J]. 中国药科大学学报, 2013, 44(1): 1-10. DOI: 10.11665/j.issn.1000-5048.20130101
引用本文: 宋洁梅, 温小安, 孙宏斌. 肺动脉高压发生机制及治疗药物的研究进展[J]. 中国药科大学学报, 2013, 44(1): 1-10. DOI: 10.11665/j.issn.1000-5048.20130101
shu
SONG Jiemei, WEN Xiaoan, SUN Hongbin. Progress in pathogenesis and therapeutic drugs of pulmonary arterial hypertension[J]. Journal of China Pharmaceutical University, 2013, 44(1): 1-10. DOI: 10.11665/j.issn.1000-5048.20130101
Citation: SONG Jiemei, WEN Xiaoan, SUN Hongbin. Progress in pathogenesis and therapeutic drugs of pulmonary arterial hypertension[J]. Journal of China Pharmaceutical University, 2013, 44(1): 1-10. DOI: 10.11665/j.issn.1000-5048.20130101
shu

肺动脉高压发生机制及治疗药物的研究进展

Progress in pathogenesis and therapeutic drugs of pulmonary arterial hypertension

    摘要
  • 摘要: 肺动脉高压（PAH）是一种以肺血管阻力和肺动脉压力渐进性升高为特征，最终导致患者右心衰竭而死亡的疾病。本文综述了近年来有关PAH发生的细胞和分子机制及其治疗药物的研究进展。

     

    Abstract: Pulmonary arterial hypertension(PAH) is a progressive and fatal disease,characterized by elevated pulmonary vascular resistance and pulmonary arterial pressure,most often resulting in right-sided heart failure.The mechanisms of action,approved PAH therapies and the latest agents in late-stage clinical development were reviewed and described in this paper.

     

    • HTML全文
    • 参考文献(0)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回

访问量：